Indoco Remedies has incorporated Warren Lifesciences Private Limited as its wholly owned subsidiary. The new entity, registered on September 26, 2026, is dedicated to pharmaceutical production.

Subsidiary launch details

The establishment of Warren Lifesciences marks a significant corporate development for Indoco Remedies, expanding its operational structure through a fully owned entity focused on pharma production. The incorporation follows the Committee of Executive Director's approval communicated in September 2026.

Strategic significance

The launch of Warren Lifesciences as a wholly owned subsidiary positions Indoco Remedies to channel dedicated resources toward pharmaceutical manufacturing through a separate legal entity, reinforcing its presence in the pharma production space. The subsidiary is registered with the Registrar of Companies, Mumbai, Maharashtra.

Capital structure and operations

Warren Lifesciences Private Limited has an authorised share capital of ₹1,00,000, divided into 10,000 equity shares of ₹10 each. Indoco Remedies will subscribe to the entire paid-up share capital, holding 100% of the shareholding. The subscription will be made via cash consideration at face value.

The subsidiary is incorporated with the object to manufacture, develop, and sell pharmaceutical products. This includes active pharmaceutical ingredients, finished formulations, and key starting materials. As the company is newly incorporated, it has not yet commenced business operations, and turnover figures are not applicable.

Indoco Remedies approved the incorporation of a wholly owned subsidiary, Warren Lifesciences Private Limited, during its Committee of Executive Directors meeting on September 18, 2026. The company received name approval from the Registrar of Companies, Mumbai, and plans to incorporate the entity in due course.

The new subsidiary will operate within the pharmaceutical sector. Indoco intends for the entity to manufacture, develop, and sell pharmaceutical products, including active pharmaceutical ingredients, finished formulations, and key starting materials.

Transaction Details

The listed entity will hold 100% shareholding in the proposed company through a cash consideration. The shares will be subscribed at a face value of ₹10 per share.

The incorporation remains subject to approvals from the Registrar of Companies, the Ministry of Corporate Affairs, and other applicable statutory or regulatory bodies. The Committee meeting commenced at 5:15 pm and concluded at 5:45 pm.